BlossomHill Therapeutics, Inc. (NASDAQ:BLSM – Get Free Report)’s share price traded down 7.2% during mid-day trading on Wednesday. The company traded as low as $23.43 and last traded at $23.43. 38,369 shares traded hands during mid-day trading, a decline of 83% from the average session volume of 223,226 shares. The stock had previously closed at $25.25.
Wall Street Analysts Forecast Growth
BLSM has been the subject of a number of research reports. Zacks Research upgraded shares of BlossomHill Therapeutics to a “hold” rating in a research report on Wednesday, September 2nd. Lifesci Capital began coverage on shares of BlossomHill Therapeutics in a research note on Tuesday, September 1st. They set an “outperform” rating and a $32.00 price target on the stock. HC Wainwright assumed coverage on shares of BlossomHill Therapeutics in a research note on Tuesday, September 1st. They issued a “buy” rating and a $35.00 price objective for the company. Guggenheim boosted their target price on shares of BlossomHill Therapeutics from $30.00 to $40.00 and gave the company a “buy” rating in a report on Monday. Finally, Leerink Partners increased their target price on BlossomHill Therapeutics from $36.00 to $40.00 and gave the stock an “outperform” rating in a research report on Monday. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $35.00.
View Our Latest Research Report on BLSM
BlossomHill Therapeutics Trading Down 8.4%
Insiders Place Their Bets
In other news, Director Carl L. Gordon purchased 625,000 shares of BlossomHill Therapeutics stock in a transaction dated Monday, August 10th. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $10,000,000.00. Following the transaction, the director directly owned 2,714,279 shares of the company’s stock, valued at approximately $43,428,464. This trade represents a 29.91% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bihua Chen purchased 312,500 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $5,000,000.00. Following the acquisition, the director owned 3,614,034 shares of the company’s stock, valued at approximately $57,824,544. This trade represents a 9.47% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders bought 1,573,900 shares of company stock worth $25,181,900.
BlossomHill Therapeutics Company Profile
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.
Further Reading
- Five stocks we like better than BlossomHill Therapeutics
- Dave’s Success Has Investors Split
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
Receive News & Ratings for BlossomHill Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlossomHill Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
